145 related articles for article (PubMed ID: 11860537)
1. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
McCluggage WG; Strand K; Abdulkadir A
Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors.
Liu A; Chen L; Ngan HY; Khoo US; Zhao Y; Cheung AN
Chin Med Sci J; 2002 Jun; 17(2):106-11. PubMed ID: 12906164
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
7. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
[TBL] [Abstract][Full Text] [Related]
9. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
10. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
12. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
13. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
Khin EE; Kikkawa F; Ino K; Suzuki T; Shibata K; Kajiyama H; Tamakoshi K; Mizutani S
Int J Gynecol Pathol; 2003 Apr; 22(2):175-80. PubMed ID: 12649673
[TBL] [Abstract][Full Text] [Related]
14. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.
Ginath S; Menczer J; Friedmann Y; Aingorn H; Aviv A; Tajima K; Dantes A; Glezerman M; Vlodavsky I; Amsterdam A
Int J Oncol; 2001 Jun; 18(6):1133-44. PubMed ID: 11351242
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
16. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
17. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of p-AKT, p-GSK3β and β-catenin in epithelial carcinoma of ovary].
Wei X; Lü QJ; Sun HX; Qi YF; Wang JO; Cao CC
Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):86-90. PubMed ID: 22455883
[TBL] [Abstract][Full Text] [Related]
19. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
[TBL] [Abstract][Full Text] [Related]
20. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
Ahmed N; Riley C; Oliva K; Stutt E; Rice GE; Quinn MA
J Pathol; 2003 Oct; 201(2):229-37. PubMed ID: 14517840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]